Headway Capital Partners’ advised fund HIP IV SCSp is pleased to have invested with GED Capital (“GED”) in the single asset continuation fund GED Strategic Partnerships I, for the acquisition of the molecular diagnostics and anatomic pathology businesses of Vitro Group (“Vitro”).
Headway looks forward to supporting GED in providing Vitro with additional time and resources to continue growing, and to focus on the launch of its new, first-in-class in-vitro diagnostics platforms in 2022. GED Strategic Partnerships I acquired GED Fund V and the founders’ remaining interest in Vitro and secured additional follow-on capital to fund its value creation plan.
Vitro (www.vitro.bio) is a global, end-to-end, diagnostics company that manufactures and distributes hardware, software and reagents. It focuses on molecular diagnostics, anatomic pathology and women’s health segments and is in the process setting up each business segment as an independent unit
Vitro has exceptional R&D capabilities, direct commercial infrastructure across Spain, Portugal and Turkey as well as a global distribution network. Vitro celebrated last year the 30-year anniversary since foundation and has expanded into more than 45 countries since then.
About GED Capital
GED is an independent asset manager founded in 1996 focused on the middle market. It currently manages over €1.0bn of capital across private equity, venture capital and infrastructure investment platforms funded by local Spanish institutions and HNW individuals, as well as a growing base of international investors.
About Headway Capital Partners
Headway Capital Partners is a London based private equity firm with advised funds of over €900 million. Headway provides bespoke liquidity and capital solutions to private equity GPs and managers, investing globally in a full range of secondary and co-investment transactions, with a focus on small to mid-size secondary direct, GP-led, and independent sponsor transactions in Europe and North America.